The “Sleip” app uses artificial intelligence (AI) to objectively analyze horse movements using just your smartphone.
DULUTH, Ga. (February 19, 2024) — A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance the detection, diagnosis and treatment of equine lameness. This partnership delivers common outcomes. Boehringer and Sleip are committed to providing innovative solutions that help veterinary professionals continue to advance their profession. Improve your horse’s care and health.
Changes in gait and signs of lameness are initially less noticeable and difficult to detect. The Sleip app can help you make a big difference. Veterinarians can use smartphones to record horse movements. No sensors or complex camera systems are required. Sleip’s AI-powered technology then analyzes the horse’s movements and displays results, including step-by-step analysis videos with synchronized biomechanical data, in the app within minutes. Your veterinarian will be able to follow up immediately, leading to improved horse health.
“Our goal is to better serve the equine veterinary community, and the Sleip app helps raise awareness of equine lameness and improve compliance with diagnosis and treatment.” Boehringer Ingel said Saskia Clay, Heim’s Global Head of Equine. “This innovative technology gives us the opportunity to make an even greater positive impact on the lives of horses and the people who care for them.”
“Sleip leverages decades of research in equine biomechanics and advances in artificial intelligence to help improve our understanding of how and why horses move the way they do.” said Erin Hernlund, DVM, Ph.D., and Chief Medical Officer. “Our vision is to improve equine welfare by making Sleip’s technology available to everyone who cares for horses, improving diagnostics, and providing individualized solutions to support early detection and prevention. “We are excited to partner with Boehringer to accomplish this mission.”
Innovative technology improves access to care for veterinarians and horse owners
This partnership, which includes Boehringer becoming a shareholder in Sleip, strengthens the value each brings to the equine veterinary community. While Boehringer is a global leader in equine health with a market-leading portfolio of treatments for various causes of lameness, Sleip uses AI to help veterinarians detect biomechanical asymmetries, It can improve the ability of veterinarians to diagnose and monitor lameness with greater sensitivity than that of veterinarians. Only human eyes. Through this collaboration, Boehringer will support the introduction of his pioneering Sleip app to the veterinary community, making this technology even more accessible.
Boehringer plans to begin promoting the Sleip app to veterinary customers in the United States and Canada later this year. Europe’s major horse market he will continue in 2025.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough treatments that change lives now and for generations to come. The company is a leading research-driven biopharmaceutical company that creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. With more than 53,000 employees, he serves more than 130 markets across his two business units, Human Pharma and Animal Health. For more information, please visit www.boehringer-ingelheim.com.
About Sleip
Sleip provides equine veterinarians with a markerless diagnostic tool that uses artificial intelligence (AI) behavior analysis to identify lameness in horses. All you need is your mobile phone.
We leverage our expertise in equine biomechanics and advances in AI to give you access to accurate horse movement analysis using only your smartphone. The Sleip app also detects and quantifies subtle asymmetries in your horse’s movements, supporting proactive preventive care. Headquartered in Stockholm, Sweden, his Sleip is a trusted partner of top equine veterinarians around the world, from large clinics to private practices. For more information, please visit sleip.com.
Notes on target audience
This press release is issued from our headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please note that information regarding approval status and approved product labeling may vary by country, and country-specific press releases on this topic may be issued in the countries in which we operate.
